No headlines found.
Globe Newswire (Tue, 7-Oct 1:09 PM ET)
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Coeptis Therapeutics Holdings trades on the NASDAQ stock market under the symbol COEP.
As of December 30, 2025, COEP stock price declined to $14.69 with 5,534 million shares trading.
COEP has a beta of -0.13, meaning it tends to be less sensitive to market movements. COEP has a correlation of 0.00 to the broad based SPY ETF.
COEP has a market cap of $78.45 million. This is considered a Micro Cap stock.
In the last 3 years, COEP traded as high as $43.80 and as low as $2.31.
The top ETF exchange traded funds that COEP belongs to (by Net Assets): VXF.
COEP has outperformed the market in the last year with a return of +303.1%, while the SPY ETF gained +16.7%. However, in the most recent history, COEP shares have underperformed the stock market with its stock returning -11.0% in the last 3 month period and -2.7% for the last 2 week period, while SPY has returned +3.8% and +1.2%, respectively.
COEP support price is $13.97 and resistance is $15.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COEP shares will trade within this expected range on the day.
